Login to Your Account

Spanish Firm Genmedica Adds $15M for Type II Diabetes Trial

By Cormac Sheridan
Staff Writer

Wednesday, October 17, 2012
Genmedica Therapeutics SL raised €12 million (US$15.5 million) in a Series B round to move its first-in-class drug candidate, GMC-252, into a Phase I trial in Type II diabetes.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription